open access
Effective treatment of severe forms of RSV and Pneumocystis jirovecii infections in a child with Down syndrome and acute lymphoblastic leukemia treated with chemotherapy
Affiliations- Student’s Scientific Association at the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, Lublin, Poland
- Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, Lublin, Poland
- Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin, Poland
open access
Abstract
There has been significant progress in acute lymphoblastic leukemia (ALL) treatment throughout the previous decades. However, infectious complications are still the main problem during cancer treatment. Literature reports show that treatment-related mortality is 2–4% and is mainly related to infection. Here, the authors report a 3-year-old patient with Down syndrome and ALL who was hospitalized in the Department of Pediatric Hematology, Oncology and Transplantology of the Medical University of Lublin. The patient was treated according to the AIEOP-BFM 2017 protocol and developed a severe co-infection of Pneumocystis jiroveci and respiratory syncytial virus during the induction phase of chemotherapy and P. jiroveci re-infection while receiving Protocol II. As a result, chemotherapy was interrupted for 51 and 31 days, respectively. The patient required the administration of broad-spectrum antibiotics, antiviral and antifungal therapy and passive oxygen therapy. Due to a severe clinical condition, the patient was also temporarily hospitalized in the Intensive Care Unit. Research revealed several risk factors for infectious complications in patients with ALL including intensive chemotherapy or Down syndrome. Therefore, despite anti-infective prophylaxis, increased medical vigilance is necessary. In the case of infectious symptoms, early diagnosis and prompt treatment should be implemented to enable the continuation of the ALL therapeutic protocol.
Abstract
There has been significant progress in acute lymphoblastic leukemia (ALL) treatment throughout the previous decades. However, infectious complications are still the main problem during cancer treatment. Literature reports show that treatment-related mortality is 2–4% and is mainly related to infection. Here, the authors report a 3-year-old patient with Down syndrome and ALL who was hospitalized in the Department of Pediatric Hematology, Oncology and Transplantology of the Medical University of Lublin. The patient was treated according to the AIEOP-BFM 2017 protocol and developed a severe co-infection of Pneumocystis jiroveci and respiratory syncytial virus during the induction phase of chemotherapy and P. jiroveci re-infection while receiving Protocol II. As a result, chemotherapy was interrupted for 51 and 31 days, respectively. The patient required the administration of broad-spectrum antibiotics, antiviral and antifungal therapy and passive oxygen therapy. Due to a severe clinical condition, the patient was also temporarily hospitalized in the Intensive Care Unit. Research revealed several risk factors for infectious complications in patients with ALL including intensive chemotherapy or Down syndrome. Therefore, despite anti-infective prophylaxis, increased medical vigilance is necessary. In the case of infectious symptoms, early diagnosis and prompt treatment should be implemented to enable the continuation of the ALL therapeutic protocol.
Keywords
acute lymphoblastic leukemia, infection, respiratory syncytial virus, Pneumocystis jiroveci, Down syndrome
About this articleTitle
Effective treatment of severe forms of RSV and Pneumocystis jirovecii infections in a child with Down syndrome and acute lymphoblastic leukemia treated with chemotherapy
Journal
Hematology in Clinical Practice
Issue
Vol 14 (2023): Continuous Publishing
Article type
Case report
Pages
1-5
Published online
2023-04-28
Page views
503
Article views/downloads
50
DOI
10.5603/HCP.2023.0001
Bibliographic record
Hematology in Clinical Practice 2023;14:1-5.
Keywords
acute lymphoblastic leukemia
infection
respiratory syncytial virus
Pneumocystis jiroveci
Down syndrome
Authors
Magdalena Ostojska
Katarzyna Karska
Monika Lejman
Joanna Zawitkowska
References (16)- Shah DS, Kumar R. Steroid resistance in leukemia. World J Exp Med. 2013; 3(2): 21–25.
- De Smedt R, Morscio J, Goossens S, et al. Targeting steroid resistance in T-cell acute lymphoblastic leukemia. Blood Rev. 2019; 38: 100591.
- Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14): 1663–1669.
- O'Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014; 124(7): 1056–1061.
- Mantadakis E. Pneumonia in children with hematological malignancies: diagnosis and approaches to management. J Fungi (Basel). 2020; 6(4).
- Maertens J, Cesaro S, Maschmeyer G, et al. et al.. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9): 2397-404, doi: 10. 1093/jac/dkw15, indexed in Pubmed. ; 27550992.
- Cordonnier C, Cesaro S, Maschmeyer G, et al. Fifth European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9): 2379–2385.
- Efstathiou C, Abidi SH, Harker J, et al. Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics. Cell Mol Life Sci. 2020; 77(24): 5045–5058.
- Hough R, Vora A. Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment). Hematology Am Soc Hematol Educ Program. 2017; 2017(1): 251–258.
- Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017; 28(2): 386–392.
- Schmidt MP, Colita A, Ivanov AV, et al. Outcomes of patients with Down syndrome and acute leukemia: a retrospective observational study. Medicine (Baltimore). 2021; 100(40): e27459.
- Patrick K, Wade R, Goulden N, et al. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. Br J Haematol. 2014; 165(4): 552–555.
- Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol. 2006; 135(5): 595–602.
- Hakim H, Dallas R, Zhou Y, et al. Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. Cancer. 2016; 122(5): 798–805.
- Zhu Y, Yang R, Cai J, et al. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. Cancer Med. 2020; 9(6): 2113–2121.
- Bateman M, Oladele R, Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: a review of current methods and novel approaches. Med Mycol. 2020; 58(8): 1015–1028.
